Myopia Management: New Technology and Future Directions

Abstract Purpose of Review The rising prevalence of myopia is a global and public health concern that prompts prevention and early management of myopia progression in children. This reviewsummarizes current evidence, emerging technologies, and future directions in pediatric myopia management, with emphasis on recent clinical trials and evolving therapeutic strategies. Recent Findings High-dose atropine, orthokeratology, and multifocal soft contact lenses have theoverall strongest evidence for reducing myopia progression but are not necessarily the best options for every child. Options such as low-dose atropine, repeated low intensity red light therapy, peripheral defocus spectacles, and increased time outdoors have also demonstrated clinically meaningful results with few adverse effects. Summary Myopia control should be individualized based on patient risk and progression. Future research should prioritize longer and more diverse trials, standardized adverse-event reporting, and direct comparisons of combined or sequential therapies. Effective management will require integrating personalized risk prediction, long-term safety, treatment optimization, and population-level behavioral strategies.